Participant flow

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma · Source last updated 2026-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   ARM A: Patients receive one of the four chemotherapy regimens ARM IA: Patients receive chemotherapy comprising docetaxel intravenously (IV) over 1 hour and cisplatin IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. ARM IIA: Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. ARM IIIA: Patients receive cisplatin IV over 1-2 hours on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. ARM IVA: Patients receive carboplatin IV over 30 minutes on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

   id

   FG000

   title

   Chemotherapy Arm (Arm A)

2. description

   ARM B: Patients receive bevacizumab in addition to the chemotherapy regimen as in arm A ARM IB: Patients receive bevacizumab IV over 30-90 minutes on day 1 and docetaxel and cisplatin as in Arm IA. ARM IIB: Patients receive bevacizumab as in arm IB and docetaxel and carboplatin as in Arm IIA. ARM IIIB: Patients receive bevacizumab as in Arm IB and cisplatin and fluorouracil as in Arm IIIA. ARM IVB: Patients receive bevacizumab as in Arm IB and carboplatin and fluorouracil as in Arm IVA.

   id

   FG001

   title

   Chemotherapy+Bevacizumab (Arm B)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         85

      2. group Id

         FG001

         num Subjects

         68

      type

      Disease progression

   2. reasons

      1. group Id

         FG000

         num Subjects

         29

      2. group Id

         FG001

         num Subjects

         58

      type

      Adverse Event

   3. reasons

      1. group Id

         FG000

         num Subjects

         13

      2. group Id

         FG001

         num Subjects

         22

      type

      Death

   4. reasons

      1. group Id

         FG000

         num Subjects

         15

      2. group Id

         FG001

         num Subjects

         25

      type

      Withdrawal by Subject

   5. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         4

      type

      Alternative therapy

   6. reasons

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         2

      type

      Other complicating disease

   7. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         9

      type

      Not start protocol therapy

   8. reasons

      1. group Id

         FG000

         num Subjects

         8

      2. group Id

         FG001

         num Subjects

         10

      type

      Lack of Efficacy

   9. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         0

      type

      Physician discretion

   10. reasons

       1. group Id

          FG000

          num Subjects

          2

       2. group Id

          FG001

          num Subjects

          2

       type

       Patient non-compliance

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         200

      2. group Id

         FG001

         num Subjects

         203

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         188

      2. group Id

         FG001

         num Subjects

         183

      type

      Eligible

   3. achievements

      1. group Id

         FG000

         num Subjects

         200

      2. group Id

         FG001

         num Subjects

         194

      type

      Start Protocol Therapy

   4. achievements

      1. group Id

         FG000

         num Subjects

         41

      2. group Id

         FG001

         num Subjects

         3

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         159

      2. group Id

         FG001

         num Subjects

         200

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

E1305 was activated on August 8, 2008 and closed on February 11,2015, with final accrual of 403 patients.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice